Braidwell LP Takes $15.66 Million Position in Kymera Therapeutics, Inc. $KYMR

Braidwell LP purchased a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 276,692 shares of the company’s stock, valued at approximately $15,661,000. Braidwell LP owned about 0.38% of Kymera Therapeutics at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Federated Hermes Inc. bought a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at about $31,622,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Kymera Therapeutics by 77.2% in the second quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock worth $1,007,000 after buying an additional 10,052 shares during the last quarter. Candriam S.C.A. boosted its holdings in shares of Kymera Therapeutics by 24.4% in the third quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock worth $10,847,000 after buying an additional 37,536 shares during the last quarter. Frontier Capital Management Co. LLC grew its position in Kymera Therapeutics by 272.7% during the second quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock valued at $21,463,000 after buying an additional 359,847 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its position in Kymera Therapeutics by 26.3% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock valued at $4,689,000 after buying an additional 22,392 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have weighed in on KYMR. Truist Financial increased their price target on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. BTIG Research reduced their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Morgan Stanley reaffirmed an “overweight” rating and issued a $123.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. Leerink Partners raised their target price on Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Finally, Stifel Nicolaus set a $114.00 target price on Kymera Therapeutics in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Insider Transactions at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 7,576 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $88.93, for a total value of $673,733.68. Following the transaction, the chief financial officer directly owned 237,483 shares of the company’s stock, valued at approximately $21,119,363.19. The trade was a 3.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the completion of the transaction, the chief executive officer owned 666,195 shares of the company’s stock, valued at $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 196,561 shares of company stock valued at $17,097,428. 16.01% of the stock is owned by corporate insiders.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $79.03 on Friday. The stock has a market cap of $6.45 billion, a PE ratio of -21.48 and a beta of 2.20. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $103.00. The firm has a fifty day moving average price of $79.21 and a 200-day moving average price of $68.32.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.88) EPS. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.